Human FCGR1A Stable Cell Line - CHO-K1

FCGR1A, also known as CD64 or Fc gamma receptor Ia, is a high-affinity receptor for the Fc region of immunoglobulin G (IgG) that plays a central role in mediating antibody-dependent immune responses. The Human FCGR1A Stable Cell Line - CHO-K1 is genetically engineered to stably express full-length human FCGR1A on the surface of Chinese hamster ovary (CHO-K1) cells. CHO-K1 is a widely used mammalian host for recombinant protein expression and cell-based assays due to its robust growth characteristics, compatibility with serum-free suspension culture, and capacity for proper post-translational modifications. The stably transfected FCGR1A gene encodes a transmembrane protein composed of three extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail that associates with the Fc receptor gamma chain to enable downstream signaling. This cell line provides a reproducible and homogeneous platform for studying the interaction between human FCGR1A and its ligands, including various IgG subclasses, antibody-drug conjugates, and therapeutic monoclonal antibodies.

This stable cell line serves as a valuable tool in immunotherapy research and drug development. It can be used to evaluate the binding affinity and specificity of antibody candidates targeting FCGR1A, assess Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, and screen for compounds that modulate Fc receptor activity. Researchers also employ this cell line in competitive binding assays to characterize bispecific antibodies, Fc fusion proteins, and other biologic therapeutics that engage the Fc gamma receptor pathway. Additionally, the Human FCGR1A CHO-K1 stable cell line supports early-stage lead optimization by enabling rapid and quantitative measurement of receptor engagement in a controlled in vitro setting. Its stable expression ensures consistent results across experiments, making it suitable for high-throughput screening applications. The line is also used in combination with immune effector cells to study how FCGR1A engagement influences downstream signaling events, cytokine release, and cellular activation, providing mechanistic insights that guide the development of next-generation antibody-based therapies for cancer, autoimmune diseases, and infectious diseases.